The Cost of Stopping (Futility) Rules Telaprevir and Boceprevir in the Treatment of Genotype 1 Hepatitis C Patients in Brazil

被引：0
|
作者：
Morais, A. D. [1 ]
Pereira, M. L. [1 ]
机构：
[1] Janssen Cilag Farmaceut, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.137
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A345 / A345
页数：1
相关论文
共 50 条
  • [31] USING BAYESIAN MODELLING TO ESTIMATE THE COST EFFECTIVENES OF TELAPREVIR AND BOCEPREVIR IN ITALIAN NAIVE PATIENTS WITH HEPATITIS C
    Ruggeri, M.
    VALUE IN HEALTH, 2014, 17 (03) : A277 - A277
  • [32] Preliminary Experience Of Hepatitis C Genotype 1 Treatment Response With Either Telaprevir Or Boceprevir Based Regimen In Patients With End Stage Renal Disease On Dialysis
    Bhamidimarri, Kalyan R.
    Sclair, Seth N.
    Franco, Melissa
    Patel, Anish
    Copado, Violet
    Junaidi, Omer
    Levy, Cynthia
    Martin, Paul
    Rudraraju, Madhavi
    HEPATOLOGY, 2013, 58 : 1143A - 1143A
  • [33] Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated With Boceprevir or Telaprevir
    Aronsohn, Andrew
    Stainbrook, Tuesdae
    Mohanty, Smruti
    Mubarak, Abdullah
    Spivey, James
    Pandya, Prashant K.
    Stewart, Thomas
    Fried, Michael W.
    Jacobson, Ira M.
    HEPATOLOGY, 2013, 58 : 218A - 218A
  • [34] COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1
    Mernagh, P.
    Feng, J.
    Del Cuore, M.
    VALUE IN HEALTH, 2013, 16 (03) : A94 - A94
  • [35] Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients
    Butt, Adeel A.
    Kanwal, Fasiha
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (01) : 96 - 104
  • [36] Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1
    Manns, Michael P.
    Markova, Antoaneta A.
    Serrano, Beatriz Calle
    Cornberg, Markus
    LIVER INTERNATIONAL, 2012, 32 : 27 - 31
  • [37] The safety and tolerability of telaprevir and boceprevir based triple therapy for hepatitis C genotype 1 in an Irish patient cohort
    El-Sherif, O.
    Quinn, C.
    Hynes, B.
    McGrath, M.
    Irish, H.
    McKiernan, S.
    Norris, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S54 - S55
  • [38] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY
    Stahmeyer, J. T.
    Schauer, S.
    Wirth, D.
    Fleischmann, J.
    Lee, S.
    Gavart, S.
    Bianic, F.
    Cure, S.
    Krauth, C.
    VALUE IN HEALTH, 2012, 15 (07) : A396 - A396
  • [39] Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection
    Cunningham, Morven
    Foster, Graham R.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (02) : 139 - 151
  • [40] Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1 Reply
    Kieran, Jennifer A.
    Schmitz, Susanne
    O'Leary, Aisling
    Walsh, Cathal
    Bergin, Colm
    Norris, Suzanne
    Barry, Michael G.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1678 - U190
12345